litlas
Log inCreate account

Michael Charlton

Active 1995–2026

138
Papers
38,074
Citations
92
h-index
131
i10-index

Citations

Citations per year for Michael Charlton1996: 2 citations1997: 2 citations1998: 2 citations1999: 24 citations2000: 28 citations2001: 30 citations2002: 56 citations2003: 59 citations2004: 85 citations2005: 68 citations2006: 89 citations2007: 74 citations2008: 61 citations2009: 108 citations2010: 99 citations2011: 113 citations2012: 140 citations2013: 272 citations2014: 273 citations2015: 370 citations2016: 456 citations2017: 395 citations2018: 493 citations2019: 1,504 citations2020: 1,767 citations2021: 1,648 citations2022: 1,314 citations2023: 958 citations2024: 1,710 citations2025: 954 citations2026: 46 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 4,108 citing papers, 24.2% of this breakdownChina: 2,093 citing papers, 12.3% of this breakdownUnited Kingdom: 991 citing papers, 5.8% of this breakdownItaly: 969 citing papers, 5.7% of this breakdownGermany: 662 citing papers, 3.9% of this breakdownJapan: 639 citing papers, 3.8% of this breakdownSpain: 599 citing papers, 3.5% of this breakdownFrance: 552 citing papers, 3.2% of this breakdownSouth Korea: 475 citing papers, 2.8% of this breakdownCanada: 436 citing papers, 2.6% of this breakdownAustralia: 383 citing papers, 2.3% of this breakdownIndia: 304 citing papers, 1.8% of this breakdown
0%24.2%Other 28.1%

Institutions

Fields

  • Medicine85.1%
  • Biochemistry, Genetics and Molecular Biology9.9%
  • Immunology and Microbiology1.3%
  • Agricultural and Biological Sciences0.7%
  • Pharmacology, Toxicology and Pharmaceutics0.7%
  • Nursing0.5%
  • Other1.8%

Topics

  • Liver Disease Diagnosis and Treatment23.7%
  • Liver Disease and Transplantation7.7%
  • Diet, Metabolism, and Disease5.7%
  • Hepatitis C virus research3.8%
  • Liver Diseases and Immunity3%
  • Diabetes, Cardiovascular Risks, and Lipoproteins2.9%
  • Other53.2%

Coauthors

All papers

Open in search
  1. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases

    Authors: Naga Chalasani, Zobair M. Younossi, Joel E. Lavine, Michael Charlton, Kenneth Cusi, Mary E. Rinella, Stephen A. Harrison, Elizabeth M. Brunt, Arun J. Sanyal - Hepatology 2017 cited by 7,293

  2. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis

    Authors: Stephen A. Harrison, Pierre Bédossa, Cynthia D. Guy, Jörn M. Schattenberg, Rohit Loomba, Rebecca Taub, Dominic Labriola, Sam E. Moussa, Guy Neff, Mary E. Rinella, Quentin M. Anstee, Manal F. Abdelmalek, Zobair M. Younossi, Seth J. Baum, Sven Francque, Michael Charlton, Philip N. Newsome, Nicolas Lanthier, Ingolf Schiefke, Alessandra Mangia, Juan M. Pericàs, Rashmee Patil, Arun J. Sanyal, Mazen Noureddin, Meena B. Bansal, Naim Alkhouri, Laurent Castéra, Madhavi Rudraraju, Vlad Ratziu - New England Journal of Medicine 2024 cited by 1,701

  3. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

    Authors: Naga Chalasani, Zobair M. Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal - Hepatology 2012 cited by 3,823

  4. Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): Beyond insulin resistance

    Authors: Alan L. Hutchison, Federica Tavaglione, Stefano Romeo, Michael Charlton - Journal of Hepatology 2023 cited by 227

  5. Effects of Belapectin, an Inhibitor of Galectin-3, in Patients With Nonalcoholic Steatohepatitis With Cirrhosis and Portal Hypertension

    Authors: Naga Chalasani, Manal F. Abdelmalek, Guadalupe García–Tsao, Raj Vuppalanchi, Naim Alkhouri, Mary E. Rinella, Mazen Noureddin, Maxmillan Pyko, Mitchell L. Shiffman, Arun J. Sanyal, Adam Allgood, Harold Shlevin, R. G. Horton, Eliezer Zomer, William Irish, Zachary Goodman, Stephen A. Harrison, Peter G. Traber, Manal F. Abdelmalek, Luis A. Balart, Brian B. Borg, Naga Chalasani, Michael Charlton, Hari S. Conjeevaram, Michael Fuchs, Reem Ghalib, Pierre Gholam, Dina Halegoua‐De Marzio, Stephen A. Harrison, Christopher Jue, Nyingi Kemmer, Kris V. Kowdley, Michelle Lai, Eric Lawitz, Rohit Loomba, Mazen Noureddin, Angelo H. Paredes, Mary E. Rinella, Don C. Rockey, Miguel Rodriguez, Raymond A. Rubin, Michael Ryan, Arun J. Sanyal, Andrew Scanga, Thomas Sepe, Mitchell L. Shiffman, Mitchell L. Shiffman, Brent Tetri, Paul J. Thuluvath, Dawn M. Torres, John M. Vierling, Julia Wattacheril, Amanda Weiland, Donald L. Zogg - Gastroenterology 2019 cited by 344

  6. The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology

    Authors: Naga Chalasani, Zobair M. Younossi, Joel E. Lavine, Anna Mae Diehl, Elizabeth M. Brunt, Kenneth Cusi, Michael Charlton, Arun J. Sanyal - Gastroenterology 2012 cited by 1,774

  7. Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes

    Authors: Petra Hirsova, Samar H. Ibrahim, Anuradha Krishnan, Vikas Verma, Steven F. Bronk, Nathan W. Werneburg, Michael Charlton, Vijay H. Shah, Harmeet Malhi, Gregory J. Gores - Gastroenterology 2016 cited by 498

  8. Association of Non-alcoholic Fatty Liver Disease with Chronic Kidney Disease: A Systematic Review and Meta-analysis

    Authors: Giovanni Musso, Roberto Gambino, James H. Tabibian, Mattias Ekstedt, Stergios Kechagias, Masahide Hamaguchi, Rolf Hultcrantz, Hannes Hagström, Seung Kew Yoon, Phunchai Charatcharoenwitthaya, Jacob George, Francisco Barrera, Svanhildur Hafliðadóttir, Einar S. Björnsson, Matthew J. Armstrong, Laurence Hopkins, Xin Gao, Sven Francque, An Verrijken, Yusuf Yılmaz, Keith D. Lindor, Michael Charlton, Robin Haring, Markus M. Lerch, Rainer Rettig, Henry Völzke, Seungho Ryu, Guolin Li, Linda L. Wong, Mariana Verdelho Machado, Helena Cortez‐Pinto, Kohichiroh Yasui, Maurizio Cassader - PLoS Medicine 2014 cited by 723

  9. Liver Transplantation 2023: Status Report, Current and Future Challenges

    Authors: Norah A. Terrault, Claire Francoz, Marina Berenguer, Michael Charlton, Julie K. Heimbach - Clinical Gastroenterology and Hepatology 2023 cited by 284

  10. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients With Nonalcoholic Fatty Liver Disease

    Authors: Rohit Loomba, Zeid Kayali, Mazen Noureddin, Peter Ruane, Eric Lawitz, Michael Bennett, Lulu Wang, Eliza Harting, Jacqueline M. Tarrant, B. Mccolgan, Chuhan Chung, Adrian S. Ray, G. Mani Subramanian, Robert P. Myers, Michael S. Middleton, Michelle Lai, Michael Charlton, Stephen A. Harrison - Gastroenterology 2018 cited by 334

  11. The ASK1 inhibitor selonsertib in patients with nonalcoholic steatohepatitis: A randomized, phase 2 trial

    Authors: Rohit Loomba, Eric Lawitz, Parvez Mantry, Saumya Jayakumar, Stephen H. Caldwell, Hays Arnold, Anna Mae Diehl, C. Stephen Djedjos, Ling Han, Robert P. Myers, G. Mani Subramanian, John G. McHutchison, Zachary Goodman, Nezam H. Afdhal, Michael Charlton, for the GS‐US‐384‐1497 Investigators - Hepatology 2017 cited by 553

  12. Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis

    Authors: Zobair M. Younossi, Rohit Loomba, Quentin M. Anstee, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael Charlton, Zachary Goodman, Naga P. Chalasani, Kris V. Kowdley, Jacob George, Keith D. Lindor - Hepatology 2017 cited by 427

  13. Complexity of ballooned hepatocyte feature recognition: Defining a training atlas for artificial intelligence-based imaging in NAFLD

    Authors: Elizabeth M. Brunt, Andrew D. Clouston, Zachary Goodman, Cynthia D. Guy, David E. Kleiner, Carolin Lackner, Dina Tiniakos, Aileen Wee, Matthew M. Yeh, Wei Qiang Leow, Elaine Chng, Yayun Ren, George Boon‐Bee Goh, Elizabeth E. Powell, Mary E. Rinella, Arun J. Sanyal, Brent A. Neuschwander‐Tetri, Zobair M. Younossi, Michael Charlton, Vlad Ratziu, Stephen A. Harrison, Dean Tai, Quentin M. Anstee - Journal of Hepatology 2022 cited by 153

  14. Expert Panel Recommendations: Practical Clinical Applications for Initiating and Monitoring Resmetirom in Patients With MASH/NASH and Moderate to Noncirrhotic Advanced Fibrosis

    Authors: Mazen Noureddin, Michael Charlton, Stephen A. Harrison, Meena B. Bansal, Naim Alkhouri, Rohit Loomba, Arun J. Sanyal, Mary E. Rinella - Clinical Gastroenterology and Hepatology 2024 cited by 136

  15. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation

    Authors: Thoetchai Peeraphatdit, Jennifer Wang, Matthew A. Odenwald, Shaomin Hu, John Hart, Michael Charlton - Hepatology 2020 cited by 264

  16. Effects of Mediterranean Diet in Patients with Nonalcoholic Fatty Liver Disease: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Randomized Controlled Trials

    Authors: Takumi Kawaguchi, Michael Charlton, Atsushi Kawaguchi, Sakura Yamamura, Dan Nakano, Tsubasa Tsutsumi, Maryam Zafer, Takuji Torimura - Seminars in Liver Disease 2021 cited by 115

  17. Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

    Authors: Quentin M. Anstee, Kathryn Jean Lucas, Sven Francque, Manal F. Abdelmalek, Arun J. Sanyal, Vlad Ratziu, Adrián Gadano, Mary E. Rinella, Michael Charlton, Rohit Loomba, Edward Mena, Jörn M. Schattenberg, Mazen Noureddin, Donald J. Lazas, George Boon‐Bee Goh, Shiv K. Sarin, Yusuf Yılmaz, Miljen Martić, Rowan Stringer, Jossy Kochuparampil, Li Chen, Gerardo Rodriguez‐Araujo, Elaine Chng, Nikolai V. Naoumov, Clifford A. Brass, Marcos Pedrosa - Hepatology 2023 cited by 65

  18. International Liver Transplantation Society Consensus Statement on Immunosuppression in Liver Transplant Recipients

    Authors: Michael Charlton, Josh Levitsky, Bashar Aqel, John O’Grady, Julie Hemibach, Mary E. Rinella, John J. Fung, Marwan Ghabril, Ray Thomason, Patrizia Burra, Ester C. Little, Marina Berenguer, Abraham Shaked, James F. Trotter, John P. Roberts, Manuel I. Rodríguez-Dávalos, Mohamed Rela, Elizabeth A. Pomfret, Caroline Heyrend, Juan F. Gallegos‐Orozco, Faouzi Saliba - Transplantation 2018 cited by 302

  19. Rational combination therapy for NASH: Insights from clinical trials and error

    Authors: Vlad Ratziu, Michael Charlton - Journal of Hepatology 2023 cited by 64

  20. Efficacy and safety of an orally administered DGAT2 inhibitor alone or coadministered with a liver-targeted ACC inhibitor in adults with non-alcoholic steatohepatitis (NASH): rationale and design of the phase II, dose-ranging, dose-finding, randomised, placebo-controlled MIRNA (Metabolic Interventions to Resolve NASH with fibrosis) study

    Authors: Neeta B. Amin, Amanda Darekar, Quentin M. Anstee, Vincent Wai‐Sun Wong, Frank Tacke, Manoli Vourvahis, Douglas S. Lee, Michael Charlton, Naim Alkhouri, Atsushi Nakajima, Carla Yunis - BMJ Open 2022 cited by 51

  21. Bifidobacteria metabolize lactulose to optimize gut metabolites and prevent systemic infection in patients with liver disease

    Authors: Matthew A. Odenwald, Huaiying Lin, Christopher Lehmann, Nicholas P. Dylla, Cody G. Cole, Jake D. Mostad, Téa E. Pappas, Ramanujam Ramaswamy, Angelica Moran, Alan L. Hutchison, M.R. Stutz, Mark Dela Cruz, Emerald Adler, Jaye Boissiere, Maryam Khalid, Jackelyn Cantoral, Fidel Haro, Rita A. Oliveira, Emily Waligurski, Thomas G. Cotter, S.H. Light, Kathleen G. Beavis, Anitha Sundararajan, Ashley M. Sidebottom, K. Gautham Reddy, Sonali Paul, Anjana Pillai, Helen S. Te, Mary E. Rinella, Michael Charlton, Eric G. Pamer, Andrew Aronsohn - Nature Microbiology 2023 cited by 65

  22. Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition

    Authors: Michael Charlton, Anuradha Krishnan, Kimberly Viker, Schuyler O. Sanderson, Sophie C. Cazanave, Andrea L. McConico, Howard Masuoko, Gregory J. Gores - American Journal of Physiology-Gastrointestinal and Liver Physiology 2011 cited by 443

  23. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

    Authors: Zobair M. Younossi, Rohit Loomba, Mary E. Rinella, Elisabetta Bugianesi, Giulio Marchesini, Brent A. Neuschwander‐Tetri, Lawrence Serfaty, Francesco Negro, Stephen H. Caldwell, Vlad Ratziu, Kathleen E. Corey, Scott L. Friedman, Manal F. Abdelmalek, Stephen A. Harrison, Arun J. Sanyal, Joel E. Lavine, Philippe Mathurin, Michael Charlton, Naga Chalasani, Quentin M. Anstee, Kris V. Kowdley, Jacob George, Zachary Goodman, Keith D. Lindor - Hepatology 2017 cited by 361

  24. Envisioning how to advance the MASH field

    Authors: Alina M. Allen, Zobair M. Younossi, Anna Mae Diehl, Michael Charlton, Jeffrey V. Lazarus - Nature Reviews Gastroenterology & Hepatology 2024 cited by 48